Geron Corp (GERN) Notes Janssen Imetelstat Trials Continuing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks close lower on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
BTIG Maintains 'Neutral' Rating on Geron (GERN) Following Imetelstat Update
September 13, 2016 6:39 AM EDTBTIG affirms Geron Corp. (Nasdaq: GERN) with a Neutral rating following an update on the ongoing imetelstat Phase II IMbark trial in MF and Phase II/III trial in MDS.
Analyst Ling Wang noted the following key points late Monday:
Imetelstat showed consistent safety profile in both trials. Safety profile of... MoreUPDATE: Geron (GERN) PT Cut to $5 at Piper Jaffray Following 'Mixed' Imetelstat Message
September 12, 2016 11:41 AM EDT(Updated - September 12, 2016 11:42 AM EDT)
(headline correction)
Piper Jaffray analyst Charles Duncan cut his price target on Geron Corporation (NASDAQ: GERN) to $5.00 (from $10.00) but maintained an Overweight rating after the company announced that partner Janssen has completed interims for both trials of its telomerase inhibitor... More
BTIG Reaffirms Geron (GERN) at 'Neutral' Following Imetelstat Update
September 12, 2016 11:13 AM EDTBTIG affirms Geron Corp. (Nasdaq: GERN) with a Neutral rating after the company provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the... More
